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S U M M A R Y
Background: Five thematic working groups composed of Italian infectious disease experts and a group
coordinator, supported by a scientiﬁc secretary, identiﬁed controversial issues in the ﬁeld of severe
healthcare-associated infections caused by multidrug-resistant organisms. The ﬁve group coordinators
received training courses on data sources and electronic databases, literature search strategies, the
scientiﬁc revision methods of quality assessment, and the construction of an evidence matrix.
Working plan and methods: The working plan identiﬁed the following step: deﬁnition of the
controversial issues and identiﬁcation of documents for a systematic literature review. A speciﬁc
methodology to classify the selected evidence was used that required the evaluation of the quality of
review documents and statement documents and evaluation of the quality of original research. An
original method to assess review documents and statement documents was proposed. Amatrixmodel to
extract and evaluate the evidence from original studies was designed using the CONSORT method to
evaluate randomized clinical trials and theNewcastle–Ottawa Quality Assessment Scale for case–control
studies, cohorts, and retrospective studies.
Quality of evidence: AmodiﬁedGRADEworking groupmethodwas applied for grading quality of evidence
and strength of recommendations. The working groups reviewed the available studies and formulated
recommendations to be voted on at the national consensus conference held in Rome in June 2009.
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The Gruppo Italiano di Studio sulle Infezioni Gravi (GISIG;
Italian Study Group on Severe Infections) is composed of expert
consultants in infectious diseases from approximately 50
hospitals nationwide. GISIG’s aim for the biennium 2008–2009
was to reach a consensus regarding the optimal management and
therapy of the ﬁve more common severe bacterial infections
(blood stream infections and endocarditis (BSI), surgical site
infections (SSI), central nervous system (CNS) infections, ortho-
pedic infections, and ventilator-associated pneumonia (VAP))
caused bymultidrug-resistant (MDR) Gram-positivemicroorgan-
isms.
Five thematic working groups composed of ﬁve or
more experts and a group coordinator, and supervised and
supported by a scientiﬁc secretary, were formed to identify
controversial issues, retrieve pertinent evidence, review avail-
able studies, and formulate recommendations for evaluation and
to be voted on at a national consensus conference to be held in
June 2009.* Corresponding author. Tel.: +39 06 55170461; fax: +39 06 55170413.
E-mail address: lauria@inmi.it (F.N. Lauria).
1201-9712/$36.00 – see front matter  2010 Published by Elsevier Ltd on behalf of In
doi:10.1016/j.ijid.2010.05.0042. Preliminary activity of the working groups
Each group presented a draft proposal of the most relevant
controversial issues in the ﬁeld based on a ﬁrst revision of the
international literature during a meeting in Milan, June 30–July 1,
2008. Then, an expert from the Cochrane Collaboration held two
methodology, two-day courses for the ﬁve group coordinators, on
how to identify the main data sources (electronic databases), build
a search strategy to identify relevant studies, review the studies
identiﬁed through electronic searching and evaluate their quality,
and build a matrix of retrieved evidence. During these courses, as a
practical exercise, some of the controversial issues identiﬁed in the
draft proposal were translated into search strategies and search
strings were launched to simulate the whole process.
3. Working plan
3.1. Deﬁnition of the list of controversial issues
The draft of the list of controversial issues was reviewed by the
scientiﬁc secretary and a restricted panel of recognized experts in
the ﬁeld, and then presented during a focused meeting to the ﬁve
working groups in March 2009 in Milan. For the presentation/
discussion of the controversial issues, a list of guiding questionsternational Society for Infectious Diseases.
Table 1
Final version of the list of controversial points
1. SSI
(i) Topical negative pressure wound treatment in deep SSI due to Gram-positive microorganisms.
(ii) Treatment of complicated skin and skin structure infections, including SSI.
2. BSI
(i) Empiric and speciﬁc therapy of BSI (either central venous catheter-related or not), of endocarditis on native or prosthetic valve, and of vascular prosthesis
caused by resistant and MDR Gram-positive microorganisms.
(ii) Role played by therapeutic drug monitoring (TDM), minimal inhibitory concentration (MIC), synergy and bactericidal assays in patients with endocarditis
caused by MDR Gram-positive microorganisms.
3. CNS infections
(i) Indications for medical treatment of patients with bacterial brain abscess.
(ii) Outcome, tolerability, cost/efﬁcacy, quality of life of different antibiotic regimens in patients with bacterial brain abscess.
(iii) Brain tissue diffusion of different antibiotic regimens in patients with bacterial brain abscess.
(iv) Best surgical approach in terms of outcome in patients with bacterial brain abscess.
4. Orthopedic infections
(i) Conservative surgical approach in the management of prosthetic joint infections.
(ii) One-stage vs. two-stage revision in managing prosthetic joint infections.
(iii) Choice regimen to manage prosthetic joint infections from methicillin-resistant staphylococci.
5. VAP
(i) Mono- or combined antibiotic therapy for VAP.
(ii) Pharmacokinetic/dynamic criteria in the rational choice of antibiotic therapy for VAP with particular focus on clinical outcome and emerging resistance to
commonly used drugs.
(iii) Criteria for de-escalation therapy.
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presented, discussed, and voted on by each thematic group.
The group participants then expressed their opinion on the
relevance of the queries, proposed modiﬁcations, and indicated
further controversial points to be included. A ﬁnal version of
the list that included the additional points was then drawn up
(Table 1).
3.2. The identiﬁcation of documents for a systematic review of the
literature
Documents were retrieved from the PubMed, EMBASE, and
Cochrane Library electronic databases, selecting those published
up until March 2009 in Italian, English, French, Spanish, and
German. In addition, the websites of the main societies of
infectious diseases (Infectious Diseases Society of America,
International Society of Infectious Diseases), respiratory diseases
(American Thoracic Society, European Respiratory Society) and
hospital infections (American Practitioner in Infection Control),
and international organizations (World Health Organization,
European Union) and international websites (Centers for Disease
Control and Prevention, National Institutes of Health, National
Guidelines Clearinghouse) were consulted.
3.2.1. Research strategies
High sensitivity, low speciﬁcity criteria were used in the
initial research strategies to ensure completeness of document
collection. The documents were chosen in the following order of
priority:
1. Statement documents (guidelines or consensus statements) and
review documents (systematic reviews of the literature, meta-
analyses) centered on the treatment of the speciﬁc pathologies
assigned to each working group and referring to controversial
aspects.
2. Original research regarding the speciﬁc query or groups of
topics not covered by statement and/or review documents,
which each working group identiﬁed as their own speciﬁc
research area.
3.3. Selection of documents for systematic revision
Documents were selected according to a three-phase proce-
dure:3.3.1. Phase 1
Based on titles and summaries, articles were selected that
contained the topics assigned to the working groups.
3.3.2. Phase 2
1. Review documents: based on the texts, articles that contained a
methods section that included the following aspects were
chosen: (a) the inclusion criteria, the considered methodology,
the study population, and the type of study; (b) the methodolo-
gy used to identify the studies; (c) the quality assessment of the
included studies.
2. Statement documents: based on the texts, articles were selected
that had the following characteristics: (a) a methods sections
that included the following aspects, (i) how questions were
deﬁned, (ii) how evidence was evaluated and synthesized, and
how evidence responded to the study question, (iii) how and by
whom the panel of experts was made up, (iv) how the experts
made their recommendations (or, in the case of conferences,
how the consensus was reached and what deﬁnition of the
iterative phase was reported, and a description of the panel and
the decision method); or (b) a methods section, even if it did not
respond to these criteria.
On this basis, the articles were classiﬁed as either ﬁrst or second
level quality.
3.3.3. Phase 3
Original research – single studies were selected using the
following procedure:
1. A bibliographical research string according to the controversial
points of each of the ﬁve groups was elaborated.
2. For each query, a research strategy was deﬁned together with
the inclusion criteria using the following strategy: population,
intervention, comparator, outcome, and design (‘PICOD’).
3. Then, the research string for each query was deﬁned and a
sensitivity and coherence test was performed, looking at both
the sensitivity and the speciﬁcity of the string.
4. Finally, for each query the following were identiﬁed: the ﬁnal
research string, an algorithm for literature selection, and the
critical points and strengths of the research strategy.
5. Additionally, to be able to answer questions that were not
covered by good quality evidence, expert opinions formulated
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these opinions had to be based on data from cases (experiences
from clinical centers, registries, case series, case reports) using a
speciﬁc methodology to ensure that data were homogeneous
and comparable.
3.4. Methodology used to classify the selected evidence
For each document, after the reference, a quality level was
reported as follows: ‘1a’, ‘1b’, ‘2’ for statement or review
documents and ‘1’ or ‘2’ for original research documents.
3.4.1. Evaluation of the quality of review documents
Documents containing a methods section were selected and
assigned to level ‘1’ if all criteria indicated in paragraph 3.3. were
satisﬁed, or to level ‘2’ if only criteria 1 and 2 were present.
Level ‘1’ was further deﬁned as ‘a’ or ‘b’ according to the
following criteria (‘a’ if all criteria were satisﬁed):
 Is there an objective?
 Is the objective clear?
 Is the bibliographical research described?
 Was the research conducted using at least three sources?
 Does the research look exhaustive?
 Did the research also include hand searching?
3.4.2. Evaluation of the quality of statement documents
Guidelines: documents were assigned to level ‘1’ if they
included a methods section meeting all or at least three out of
four criteria indicated in paragraph 3.3., otherwise they would be
classiﬁed as level ‘2’.
Consensus conferences: documents were assigned to level ‘1’ if
these included amethods sectionmeeting all or at least three out of
ﬁve criteria indicated in paragraph 3.3., otherwise they would be
classiﬁed as level ‘2’.
3.4.3. Evaluation of the quality of original research
A matrix was created to extract evidence from original studies,
using the CONSORT1–4 method to evaluate randomized clinical
trials (RCT), and the Newcastle–Ottawa Quality Assessment Scale5
for case–control studies, longitudinal cohorts, and retrospective
studies with comparative evaluations.
To include data from case reports, these were made homoge-
neous using a predeﬁned format both for single case reports and
case series. This scheme was agreed with the Faculty. Publications
including case reports or case series were evaluated using the
criteria published by the Editorial Board of the BioMed Central
(BMC) Cases Journal and journal of Medical Case Reports.6,7
4. Grading quality of evidence and strength of
recommendation
4.1. Applying the GRADE Working Group method
Following the GRADEWorking Group8method , four evaluation
criteria were considered (outlined below).
Statement and review documents: (1) study design; (2) study
quality; (3) reproducibility/consistency of the study; (4) clarity of
aim/applicability.
Original research and data from case reports: (1) study design
(e.g., RCT, comparative study); (2) quality and limitations of the
study (e.g., adequacy of allocation concealment, blinding, follow-
up); (3) reproducibility (‘consistency’) of results; (4) direct
applicability (‘directness’) of results in terms of: (i) population
(e.g., patients are older, sicker, etc.), (ii) intervention (e.g., drugs
that differ from those in the studies but are within the same class),(iii) outcome (clinically relevant vs. surrogate), (iv) comparisons
(direct comparisons of interventions: A–C instead of indirect
comparison A–B and C–B).
4.2. Quality of the methodology of original articles and statement and
review documents
When applying the methodology noted previously, the selected
articles were classiﬁed into quality levels according to their
conﬁdence level (i.e., the probability that future research could
change the research results), outlined below.
4.2.1. High level
 Meta-analyses and/or systematic reviews evaluated as level 1a
(documents with the following requisites: (1) study inclusion
criteria; (2) study identiﬁcation method; (3) quality assessment
of included studies; and responding to a check-listmade up of six
criteria—see section 3.4.1.).
 Level 1 guidelines (including a methods sections or three out of
four among the following criteria: (1) how were the questions
deﬁned; (2) how was the evidence responding to the questions
identiﬁed, evaluated, and synthesized; (3) how and by whom
was the panel of experts composed; (4) how did the experts
make their recommendations).
 Level 1 consensus conference (including a methods sections or
three out of ﬁve of the following criteria: (1) how were the
questions deﬁned; (2) how was the evidence responding to the
questions identiﬁed, evaluated, and synthesized; (3) how and by
whom was the panel of experts composed; (4) deﬁnition of
iterative phases; (5) a description of the panel and the decision
method).
 Conﬁdence level: It is very unlikely that the results will be
changed by further research.
4.2.2. Intermediate level
 Meta-analyses and/or systematic reviews evaluated as level 1b
(documents with the following requisites: (1) study inclusion
criteria; (2) study identiﬁcation method; (3) quality assessment
of included studies, but not responding to the criteria in the
check-list).
 Conﬁdence level: It is likely that this could be changed by further
research.
4.2.3. Low level
 Meta-analyses and/or systematic reviews evaluated as level 2
(no requisites as for 1a and 1b).
 Level 2 guidelines (no requisites as for 1).
 Level 2 consensus conference (no requisites as for 1).
 Conﬁdence level: It is very likely that this could be changed by
further research.
4.2.4. Very low level
 Conclusions and indications based on expert opinion, included in
statement or review documents.
 Conﬁdence level: Any estimate of effect is very uncertain.
4.3. Quality of evidence and strength of the recommendation: review
and statement documents
The quality level of an article was considered to be directly
correlated to its level of conﬁdence. Consequently, adopting the
Table 4
Quality of evidence and strength of the recommendation: original research documents
Quality of evidence Final score and conﬁdence level of evidence Strength of the recommendation
High 4 very unlikely that it would be changed by future research A
Intermediate =3 likely that it would be changed by future research B
Low =2 very likely that it would be changed by future research C
Very low =1 the estimate of effect was very uncertain D
Table 3
Matrix for the assignment of quality score (GRADE method)
Study designa # " Total quality scoreb
Study limits
(1, 2)
Consistency
(1)
Directness
(1, 2)
Accuracy
(1)
Bias
(1)
Association
evidence (+1, +2)
Dose–response
gradient (+1)
Confounder
bias (+1)
a RCT=4, observational study=2, etc.
b >4: high; =3: intermediate; =2: low; =1: very low.
Table 2
Quality of evidence and strength of the recommendation: review and statement documents
Quality of evidence Type and classiﬁcation of evidence Strength of recommendation
High Recommendation derived/supported by: A
- Level 1 statement documents based on good quality evidence
- Systematic reviews with a good quality methodology (level 1a)
Intermediate Recommendation derived/supported by: B
- Level 1 statement documents based on lower quality evidence
- Systematic reviews with a good quality methodology (level 1b)
Low Indications/recommendation based on: C
- Level 2 statement documents
- Level 2 systematic reviews
Very low Expert opinions, or indications deriving from recommendations by a panel of experts D
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recommendation was assigned as in Table 2.
4.4. Quality of evidence and strength of the recommendation: original
research documents
4.4.1. Initial criteria for quality scores
Score applied to the study design as declared in the article:
 High = randomized controlled clinical studies (4).
 Intermediate = controlled but not randomized studies (3).
 Low = non-randomized cohort studies, observational studies, or
retrospective studies, e.g., case–controls (2).
 Very low = case studies, cases series, others (1).
4.4.2. Down-grading of quality scores
 Serious (1) or very serious (2) limitation to study quality.
 Important inconsistency (1).
 Some (1) or major (2) uncertainty about directness.
 Imprecise or sparse data (1).
 High probability of reporting bias (1).
4.4.3. Up-grading of quality scores
 Strong evidence of association—signiﬁcant relative risk of
>2 (<0.5) based on consistent evidence from two or
more observational studies, with no plausible confounders
(+1).
 Very strong evidence of association—signiﬁcant relative risk of
>5 (<0.2) based on direct evidence with no major threats to
validity (+2). Evidence of a dose–response gradient (+1).
All plausible confounders would have reduced the effect
(+1).
4.4.4. Matrix for the assignment of quality score (GRADEmethod) and
strength of the recommendation
The evidence table (Table 3) was therefore applied to each of
the considered articles. On the basis of the ﬁnal score deﬁned for
each study (right hand column of Table 3), considering that the
conﬁdence level (probability that the evidencewould bemodiﬁed
by future research) was directly correlated to the score,
the strength of the recommendation was assigned according to
Table 4.
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